

# Mavorixafor (hydrochloride)

Catalog No: tcsc1111



## Available Sizes

---

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**Formula:**

$C_{21}H_{30}Cl_3N_5$

**Pathway:**

GPCR/G Protein;Immunology/Inflammation;Anti-infection

**Target:**

CXCR;CXCR;HIV

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

AMD-070 (hydrochloride)

**Observed Molecular Weight:**

458.86


## Product Description

Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available **CXCR4** antagonist, with an **IC<sub>50</sub>** value of 13 nM against CXCR4 <sup>125</sup>I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an **IC<sub>50</sub>** of 1 and 9 nM, respectively.

IC50 & Target: IC50: 13 nM (<sup>125</sup>I-SDF-CXCR4), 1 nM (HIV-1 (NL4.3 strain), in MT-4 cells), 9 nM (HIV-1 (NL4.3 strain), in PBMCs)<sup>[1]</sup>

**In Vitro:** Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC<sub>50</sub> value of 13 nM against CXCR4 <sup>125</sup>I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC<sub>50</sub> of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) <sup>[1]</sup>. Mavorixafor (AMD-070) (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells<sup>[2]</sup>.

**In Vivo:** Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!